2725-4910

ANNALS OF THE NEW YORK ACADEMY OF SCIENCES Volume 696

IMMUNOSUPPRESSIVE AND ANTIINFLAMMATORY DRUGS

Edited by Anthony C. Allison, Kevin J. Lafferty, and Hans Fliri

¢



10.00

The New York Academy of Sciences New York, New York 1993 Volume 696 November 30, 1993

IMMUNOSUPPRESSIVE AND ANTIINFLAMMATORY DRUGS^a

Editors and Conference Organizers ANTHONY C. Allison, Kevin J. Lafferty, and Hans Fliri

CONTENTS	
Novel Immunosuppressive and Antiinflammatory Drugs: A 1993 Perspective. By ANTHONY C. ALLISON	xi
Part I. Immunobiology of Cyclosporins, FK-506, and Rapamycin	
Immunosuppressive Profile of Rapamycin. By SUREN N. SEHGAL	1
The Mechanism of Action of FK-506 and Cyclosporin A. By GREG WIEDERRECHT, ELSA LAM, SHIRLEY HUNG, MARY MARTIN, and NOLAN SIGAL	9
Calcineurin Is a Key Signaling Enzyme in T Lymphocyte Activation and the Target of the Immunosuppressive Drugs Cyclosporin A and FK506. By NEIL A. CLIPSTONE and GERALD R. CRABTREE	20
Rapamycin Inhibits p34 ^{cdc2} Expression and Arrests T Lymphocyte Proliferation at the G1/S Transition. <i>By</i> W. MICHAEL FLANAGAN and GERALD R. CRABTREE	31
Proline Isomerases in Microorganisms and Small Eukaryotes. By CHARLES HEMENWAY and JOSEPH HEITMAN	38
Cyclosporins: Structure-Activity Relationships. <i>By</i> HANS FLIRI, GOETZ BAUMANN, ALBERT ENZ, JUERG KALLEN, MARCEL LUYTEN, VINCENT MIKOL, RAO MOVVA, VALERIE QUESNIAUX, MAX SCHREIER, MALCOLM WALKINSHAW, ROLAND WENGER, GERHARD ZENKE, and MAURO ZURINI	47
An FKBP-Rapamycin-Sensitive, Cyclin-Dependent Kinase Activity that Correlates with the FKBP-Rapamycin-Induced G1 Arrest Point in MG-63 Cells. By MARK W. ALBERS, ERIC J. BROWN, AKITO TANAKA, RICHARD T. WILLIAMS, FREDERICK L. HALL, and STUART L. SCHREIBER	54

Part II. Novel Immunosuppressive Drugs

^{*a*}This volume is the result of a conference entitled Immunosuppressive and Antiinflammatory Drugs held on April 12–15, 1993 in Orlando, Florida and sponsored by the New York Academy of Sciences.

Human Type I and II IMP Dehydrogenases as Drug Targets. By YUTAKA NATSUMEDA and STEPHEN F. CARR	88
Immunosuppression by Discodermolide. By Ross E. Longley, Sarath P. GUNASEKERA, DENISE FAHERTY, JOHN MCLANE, and FRANCIS DUMONT	94
Brequinar Sodium, Mycophenolic Acid, and Cyclosporin A Inhibit Different Stages of IL-4- or IL-13-Induced Human IgG4 and IgE Production In Vitro. By CHIA-CHUN J. CHANG, GREGORIO AVERSA, JUHA PUNNONEN, HANS YSSEL, and JAN E. DE VRIES	108
Deoxyspergualin: Mechanism of Action Studies of a Novel Immunosuppressive Drug. By MARK A. TEPPER	123
Part III. Novel Antiinflammatory Strategies	
The IL-1β Converting Enzyme as a Therapeutic Target. By DOUGLAS K. MILLER, JIMMY R. CALAYCAY, KEVIN T. CHAPMAN, ANDREW D. HOWARD, MATTHEW J. KOSTURA, SUSAN M. MOLINEAUX, and NANCY A. THORNBERRY	133
Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors. ByJ. C. LEE, A. M. BADGER, D. E. GRISWOLD, D. DUNNINGTON,A. TRUNEH, B. VOTTA, J. R. WHITE, P. R. YOUNG, and P. E. BENDER	149
Coordinate Inhibition by Some Antioxidants of TNFα, IL-1β, and IL-6 Production by Human Peripheral Blood Mononuclear Cells. By ELSIE M. EUGUI, BARBARA DELUSTRO, SUSSAN ROUHAFZA, ROBERT WILHELM, and ANTHONY C. ALLISON	171
Mycophenolic Acid and Some Antioxidants Induce Differentiation of Monocytic Lineage Cells and Augment Production of the IL-1 Receptor Antagonist. <i>By</i> RUTH V. WATERS, DONNA WEBSTER, and ANTHONY C. ALLISON	185
Cycloxygenase Gene Expression in Inflammation and Angiogenesis. By TIMOTHY HLA, ARI RISTIMÄKI, SUSAN APPLEBY, and JAVIER G. BARRIOCANAL	197
Preclinical and Clinical Activity of Zileuton and A-78773. <i>By</i> R. L. BELL, C. LANNI, P. E. MALO, D. W. BROOKS, A. O. STEWART, R. HANSEN, P. RUBIN, and G. W. CARTER	205
Part IV. Immunosuppressive Drugs for Transplantation	
rait iv. minunosuppressive Drugs for Transplantation	
Use of Brequinar Sodium for Transplantation. By DONALD V. CRAMER, FRANCES A. CHAPMAN, and LEONARD MAKOWKA	216
Cytidine Potentiates the Inhibitory Effect of Brequinar Sodium on Xeno- MLR, Antibody Production, and Concordant Hamster to Rat Cardiac Xenograft Survival. <i>By</i> JACKY WOO, LUIS A. VALDIVIA, FAN PAN, SUSANNA CELLI, JOHN J. FUNG, and ANGUS W. THOMSON	227
Efficacy of FK506 in Renal Transplantation. <i>By</i> SHIRO TAKAHARA	235
Incidence of CD4 ⁺ IL-2Rα ⁺ and CD4 ⁺ T-Cells in Progressive Multiple Sclerosis and the Influence of Short-Term (3 Months) FK 506 Therapy. By ANGUS W. THOMSON, JACKY WOO, BONNIE LEMSTER, WILLIAM IRISH, LINDA L. HUANG, PATRICIA B. CARROLL, HORATIO R. RILO, KAREEM ABU-ELMAGD, and BENJAMIN EIDELMAN	245

FK 506 Inhibits Cytokine Gene and Adhesion Molecule Expression in Psoriatic Skin Lesions. <i>By</i> B. LEMSTER, H. R. RILO, P. B. CARROLL, M. A. NALESNIK, and A. W. THOMSON	250
Inhibitory Effect of FK 506 on Autoimmune Thyroid Disease in the PVG Rat. <i>By</i> K. TAMURA, J. WOO, N. MURASE, M. NALESNIK, and A. W. THOMSON	257
Deoxyspergualin: Mode of Action and Clinical Trials. By SEIICHI SUZUKI	263
Combination of Immunosuppressive Drugs for Organ Transplantation. By TAKENORI OCHIAI, YOSHIO GUNJI, MATSUO NAGATA, and KAICHI ISONO	270
Immunosuppressant Combinations in Primate Cardiac Xenografts: A Review. By ROBERT P. MCMANUS, DANIEL P. O'HAIR, RICHARD KOMOROWSKI, and J. PAUL SCOTT	281
Part V. Clinical Applications of Immunosuppressive and Antiinflammatory Drugs	
Optimizing Combination Chemotherapy for Rheumatoid Arthritis. By DANIEL E. FURST	285
Effects of Nonsteroidal Antiinflammatory Drugs on Bone Loss in Chronic Inflammatory Disease. By MARJORIE K. JEFFCOAT, MICHAEL S. REDDY, LARRY W. MORELAND, and WILLIAM J. KOOPMAN	292
Cyclooxygenase Inhibitors Vary Widely in Potency for Preventing Cytokine- Induced Bone Resorption. <i>By</i> ANTHONY C. ALLISON, RUEI-CHEN CHIN, and YVONNE CHENG	303
Treatment of Autoimmune Uveitis. <i>By</i> SCOTT M. WHITCUP and ROBERT B. NUSSENBLATT	307
Immunosuppressive Treatment of Chronic Liver Disease. <i>By</i> E. ANTHONY JONES and NORA VALERIA BERGASA	319
Part VI. Treatment of Insulin-Dependent Diabetes Mellitus	
Mycophenolate Mofetil Can Prevent the Developmentof Diabetes in BB Rats. By LIMING HAO, SIU-MEI CHAN, and KEVIN J. LAFFERTY	328
The Use of Nicotinamide in the Prevention of Type 1 Diabetes. <i>By</i> R. B. ELLIOTT, C. C. PILCHER, A. STEWART, D. FERGUSSON, and M. A. MCGREGOR.	333
Early Diagnosis and Specific Treatment of Insulin-Dependent Diabetes. By NOEL MACLAREN, ANDREW MUIR, JANET SILVERSTEIN, YAO-HUA SONG, JIN XIONG SHE, JEFFREY KRISCHER, MARK ATKINSON, and DESMOND SCHATZ	342
Lessons Learned from Use of Cyclosporine for Insulin-Dependent Diabetes Mellitus: The Case for Immunotherapy for Insulin-Dependent Diabetics Having Residual Insulin Secretion <i>By</i> JEFFREY L. MAHON, JOHN DUPRE, and CALVIN R. STILLER	351
Strategies in Immunotherapy of Insulin-Dependent Diabetes Mellitus. By JEAN-FRANÇOIS BACH	364
New Strategies for Clinical Islet Transplantation: The Role of Purified Grafts and Immunosuppressive Therapy. <i>By</i> PAUL F. GORES, DIXON B. KAUFMAN, and DAVID E. R. SUTHERLAND	377

Poster Papers

Index of Contributors	23
-----------------------	----